Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unione Europea - italiano - EMA (European Medicines Agency)

gilead sciences ireland unlimited company - lenacapavir sodium - infezioni da hiv - antivirali per uso sistemico - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 e 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 e 5.

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - levetiracetam - epilessia - altri antiepilettici - levetiracetam sun è indicato come monoterapia nel trattamento delle crisi parziali con o senza generalizzazione secondaria in pazienti dai 16 anni di età con recentemente diagnosticato l'epilessia. levetiracetam sun è indicato come terapia aggiuntiva:nel trattamento di parziale-inizio convulsioni con o senza secondaria generalizzazione in adulti e bambini dai quattro anni di età con epilessia;nel trattamento delle crisi miocloniche in adulti e adolescenti a partire dai 12 anni di età con epilessia mioclonica giovanile;nel trattamento delle primarie generalizzate tonico-cloniche in adulti e adolescenti a partire dai 12 anni di età con epilessia generalizzata idiopatica. levetiracetam sun concentrate è un'alternativa per i pazienti quando la somministrazione orale non è al momento fattibile.

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - temozolomide - glioma; glioblastoma - agenti antineoplastici - temozolomide sun è indicato per il trattamento di:pazienti adulti con nuova diagnosi di glioblastoma multiforme in concomitanza a radioterapia (rt) e in seguito come monoterapia trattamento;i bambini dall'età di tre anni, adolescenti e pazienti adulti con glioma maligno, come il glioblastoma multiforme o l'astrocitoma anaplastico, che mostra recidiva o progressione dopo la terapia standard.

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenem sodico - infezioni batteriche - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 e 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - omeostasi del calcio - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sun store health care ag - anisi aetheroleum, eucalypti aetheroleum, levomentholum, polygalae radicis extractum ethanolicum siccum (polygala senega l., radix), glycerolum, liquiritiae succus - sun store pastiglie bronchiques - anisi aetheroleum 3.1 mg, eucalypti aetheroleum 1.4 mg, levomentholum 3.9 mg, polygalae radicis extractum ethanolicum siccum (polygala senega l., radix) 1.4 mg, der: 3-6:1, auszugsmittel ethanolum 30 % m/m, maltodextrinum, acaciae gummi, glycerolum 60 mg, liquiritiae succus 129.6 mg, sorbitolum 716 mg, acesulfamum kalicum, aqua purificata, pro pastillo. - nella tosse da raffreddore - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - atosiban (as acetate) - nascita prematura - altre gynecologicals - atosiban è indicato per ritardare l'imminente nascita pre-termine in stato di gravidanza, le donne adulte con:regolare le contrazioni uterine di almeno 30 secondi di durata, ad un tasso di ≥ 4 per 30 minuti;una dilatazione cervicale da 1 a 3 cm (0-3 per nulliparas) e appianamento di ≥ 50%;età di gestazione dalle 24 fino a 33 settimane complete;una normale frequenza cardiaca fetale.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sun store health care ag - carbocisteinum - sirup - carbocisteinum 750 mg, ethanolum 96 per centum 59 mg, natrii hydroxidum, sorbitolum liquidum non cristallisabile 8.528 g, acidum citricum monohydricum, aqua purificata, ammonii glycyrrhizas, aromatica (banane, kirsche), e 150(a), propylis parahydroxybenzoas natricus 4 mg, e 219 37 mg ad solutionem pro 15 ml corresp. natrium 100.8 mg. - mukolytikum - synthetika